课题基金 / 基金详情

ACTG382 PHARMACOKINETICS, SAFETY, TOLERABILITY&ANTIVIRAL ACTIVITY OF

ACTG382 PHARMACOKINETICS, SAFETY, TOLERABILITY&ANTIVIRAL ACTIVITY OF
ACTG382 药代动力学、安全性、耐受性
批准号：
6264880
负责人：
MARGARET A KELLER
金额：
$0.1万
依托单位：
LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER
依托单位国家：
美国
项目类别：
财政年份：
1998
资助国家：
美国
项目状态：
已结题
起止时间：
1998-12-01 至 1999-11-30
来源：
https://reporter.nih.gov/project-details/6264880
关键词：
AIDS therapy HIV infections antiAIDS agent child (0-11) clinical research clinical trial phase I combination chemotherapy dosage drug adverse effect drug screening /evaluation human subject human therapy evaluation pharmacokinetics protease inhibitor reverse transcriptase inhibitors

项目摘要

项目成果

MARGARET A KELLER的其他基金

相似基金

相关文献

中文摘要
翻译
这是一项关于DMP 266的临床研究，DMP 266是一种用于治疗儿童HIV感染的实验性药物。本研究将试图确定dmp266对儿童是否安全有效，并确定儿童的适当剂量。该药将与FDA批准的药物奈非那韦（NFV）联合使用。该研究还将确定NFV与dmp266联合使用时儿童的适当剂量。除了患者已经服用的AZT、d4T、ddI或3TC等常用抗艾滋病毒药物外，还将服用这些药物。药物的剂量可能会根据这些药代动力学研究的结果而改变。
英文摘要
This is a clinical study of DMP 266, an investigational drug being studied for the treatment of HIV infection in children. This study will try to find out if DMP 266 is safe and effective for children and determine the proper dosage in children. This drug will be taken in combination with the FDA approved drug Nelfinavir(NFV). The study will also determine the appropriate dose of NFV in children when given in combination with DMP 266.These medicines will be taken in addition to the usual anti-HIV medicine the patient is already taking like AZT, d4T, ddI or 3TC. The dose of the medicines may change depending on the results of these pharmacokinetic studies.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
INTENSIVE PHARMACOKINETIC STUDIES OF ANTIRETROVIRAL DRUG COMBINATIONS HIV
INTENSIVE PHARMACOKINETIC STUDIES OF ANTIRETROVIRAL DRUG COMBINATIONS
Two-Dimensional 3 Tesla MRS of the Brain in HIV- Infected Youth
PHARMACOKINETIC PROPERTIES OF ANTIRETROVIRAL THERAPY DURING PREGNANCY
海外基金